Recombinant Human Siglec-8 Protein, His Tag, 100 µg

Background
Siglec-8 is also known as SIGLEC8, SAF2, SIGLEC-8, SIGLEC8L and sialic acid binding Ig like lectin 8. Siglec-8 was first identified by CD33 homology screening of ESTs from a cDNA library generated from a patient diagnosed with idiopathic hypereosinophilic syndrome and was originally termed SAF-2 (sialoadhesin family 2). At the tissue level, Siglec-8 mRNA was found to be most highly expressed in lung, PBMCs, spleen, and kidney. Two splice variants of Siglec-8 exist. The initially characterized form contains 431 amino acid residues in total, subsequently, a longer form of Siglec-8, initially termed Siglec-8L. Both forms of Siglec-8 are found in eosinophils and contain a V-set domain with lectin activity and two C2-type Ig repeat domains in the extracellular region.

Source
Recombinant Human Siglec-8, His Tag (SI8-H52H8) is expressed from human 293 cells (HEK293). It contains AA Met 17 - Ala 363 (Accession # Q9NYZ4-1).
Predicted N-terminus: Met 17

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 39.7 kDa. The protein migrates as 50-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS with Arginine, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1)  "Emerging therapies for eosinophilic esophagitis"
Meek, Hemstreet
Pharmacotherapy (2023)
(2)  "Structures of the Inhibitory Receptor Siglec-8 in Complex with a High-Affinity Sialoside Analogue and a Therapeutic Antibody"
Lenza, Atxabal, Nycholat et al
JACS Au (2023) 3 (1), 204-215
(3)  "Drug delivery targets and strategies to address mast cell diseases"
Rische, Thames, Krier-Burris et al
Expert Opin Drug Deliv (2023) 20 (2), 205-222
Showing 1-3 of 158 papers.